Clinical Guides
Bladder Cancer
A clinically focused guide to recognising haematuria, confirming and staging bladder cancer, separating non-muscle-invasive from muscle-invasive disease, and coordinating safe multidisciplinary care in India.
MedNext Academy | 15 min read
Bladder Cancer
A clinically focused guide to recognising haematuria, confirming and staging bladder cancer, separating non-muscle-invasive from muscle-invasive disease, and coordinating safe multidisciplinary care in India.
Summary
Bladder cancer is a malignant neoplasm arising most often from the urothelium. Its central clinical distinction is whether tumour remains non-muscle-invasive—carcinoma in situ, Ta or T1—or has invaded detrusor muscle, because prognosis, staging and treatment change substantially at that boundary. Visible haematuria, classically painless and intermittent, is the best-known presentation, but absence of pain or spontaneous clearing must not reassure. Irritative lower urinary tract symptoms, recurrent apparently sterile dysuria, pelvic pain, obstruction or constitutional decline can also occur. Urothelial cancer may be multifocal and can involve the renal pelvis, ureter or urethra, so assessment is not limited to a single visible bladder lesion.
Diagnosis requires direct evaluation and histopathology. Cystoscopy defines visible mucosal disease; transurethral resection of bladder tumour obtains tissue, aims to remove visible non-muscle-invasive tumour and must provide adequate material—including detrusor muscle when appropriate—for grade and depth assessment. Urine cytology is an adjunct for high-grade disease and carcinoma in situ, not a replacement for cystoscopy. Cross-sectional imaging assesses upper tracts, local extension, nodes and distant disease according to risk. A pathology report should state histological type, grade, lamina propria and muscle invasion, variant morphology and lymphovascular invasion where present.
Treatment ranges from complete transurethral resection and risk-adapted intravesical therapy to radical cystectomy, bladder-preserving trimodality treatment, systemic therapy and symptom-directed care. Decisions require urology, pathology, radiology, medical and radiation oncology expertise, renal-function assessment and discussion of urinary, sexual, bowel and fertility consequences. This educational draft remains quarantined following MedNext Clinical Team review and cannot determine an individual's diagnosis, drug regimen or eligibility for bladder preservation.
How Common Is It?
Bladder cancer is less common in India than oral, breast, lung, cervical and colorectal cancers, but it is clinically important because haematuria is frequent, recurrence after treatment is common and surveillance can extend for years. The IARC Global Cancer Observatory India fact sheet for 2022 provides modelled estimates across cancer sites and shows that India's overall cancer burden is large and heterogeneous. Site-specific bladder estimates should be obtained from the underlying Cancer Today dataset or an applicable population-based registry rather than inferred from the fact sheet's ranked summary. Modelled national numbers are not a live registry and should not be presented as exact counts.
Incidence rises strongly with age and is higher in men, reflecting different exposure patterns as well as biology and ascertainment. However, women and younger adults can develop the disease. Women may experience diagnostic delay when visible blood is attributed to urinary infection or vaginal bleeding without confirming the source. Regional incidence can vary with tobacco exposure, occupational history, schistosomiasis prevalence, industrialisation, population age structure and the completeness of cancer registration. Migrant history matters because Schistosoma haematobium-associated squamous carcinoma is linked to endemic exposure, although urothelial carcinoma remains the dominant histology in most Indian practice.
Incidence, mortality, prevalence and recurrence are different measures. A patient treated for a superficial-appearing lesion may face repeated recurrences without metastatic disease, while muscle-invasive cancer can progress rapidly. Population frequency therefore does not set the urgency of an individual's haematuria. For service planning, local cystoscopy capacity, pathology quality, access to re-resection, intravesical agents, staging and definitive treatment are more actionable than a single national rank. For counselling, explain that stage, grade, carcinoma in situ, completeness of resection, renal function, comorbidity and response to therapy shape outcome more than a headline statistic.
Risk Factors
Tobacco smoking is the most important preventable risk factor for urothelial bladder cancer. Risk relates to cumulative exposure, but no threshold is safe and former smokers remain at increased risk for years. Ask about cigarettes, bidis, hookah and other smoked products without assuming chewing tobacco has the same quantified bladder effect. Smoking cessation remains worthwhile after diagnosis because it improves general health and may reduce competing surgical and cardiovascular risks. A blame-free history is essential: many patients have never smoked, and an exposure history cannot diagnose or exclude cancer.
Occupational exposure to aromatic amines and related chemicals has occurred in dye, rubber, leather, paint, printing, metal and petroleum-associated work. Record the actual job, task, duration, protective measures and latency rather than merely naming an industry. Previous pelvic radiotherapy, cyclophosphamide exposure, chronic urothelial irritation and selected inherited cancer syndromes can increase risk. Chronic Schistosoma haematobium infection is associated particularly with squamous-cell carcinoma; enquire about residence or freshwater exposure in endemic regions, but do not use ethnicity as a surrogate for infection. Long-term catheters and neurogenic bladder can be associated with chronic inflammation and require symptom-aware follow-up.
Clinical risk assessment also anticipates management. Document renal function, hearing, neuropathy and heart failure because these can affect cisplatin fitness; anticoagulants and antiplatelets because haematuria still needs evaluation; previous abdominal or pelvic operations; inflammatory bowel disease; frailty; cognition; baseline urinary continence; sexual function; fertility priorities and ability to self-care after diversion. Social determinants—including travel to a tertiary centre, stoma-supply access, loss of wages and family support—can alter whether a theoretically optimal plan is deliverable. Coffee, artificial sweeteners or a single urinary infection should not be labelled causal. Risk-factor control complements, but never substitutes for, investigation of unexplained haematuria.
Diagnosis
History
Clarify whether blood is visible or detected only on testing, its duration, intermittency, clots, pain and relation to voiding. Ask about dysuria, urgency, frequency, nocturia, recurrent culture-negative symptoms, flank or pelvic pain, weak stream, retention and weight or appetite change. Establish whether bleeding could be vaginal, rectal or medication-associated without dismissing urinary malignancy in a person taking anticoagulants. Record tobacco, occupational, radiotherapy, cyclophosphamide, catheter and endemic-travel exposures; prior urothelial cancer; stones; infection; renal disease; allergies and contrast risk. Fever, sepsis symptoms, anuria, clot retention or severe anaemia change immediate priorities.
Examination
Assess haemodynamic stability, pallor, fever, hydration and performance status. Examine the abdomen for suprapubic distension, tenderness, masses, scars or stomas, and assess renal angles. Pelvic, rectal or genital examination is selective and consent-based when needed to identify another bleeding source, local extension or an alternative diagnosis. Look for lymphadenopathy, leg oedema, bone tenderness or neurological signs when advanced disease is possible. A normal physical examination is common in early bladder cancer and must not close the pathway.
Investigations
Urinalysis, microscopy and culture can document haematuria or infection; full blood count and renal profile assess consequences and procedural fitness. Cystoscopy is required when bladder cancer is suspected and cannot be replaced by cytology or a commercial urinary biomarker. Ultrasound and/or CT urography evaluate haematuria and upper tracts according to renal function and local protocol. TURBT should document site, size, number and morphology, resect visible tumour systematically and provide histology with detrusor muscle for reliable staging when indicated. Cytology supports detection of high-grade disease or carcinoma in situ. Suspected muscle invasion requires chest, abdomen and pelvis staging, including urographic assessment; MRI, if selected for primary local staging, is ideally performed before TURBT. Pathology and imaging must be reviewed together when findings conflict.
Differential Diagnosis
Haematuria has a broad differential and the source must be localised. Urinary infection can cause dysuria, pyuria and bleeding, but culture evidence and response should be reviewed; persistent or recurrent visible haematuria after treatment warrants cancer evaluation. Urolithiasis often causes colic yet may be painless. Benign prostatic enlargement, prostatitis, urethral disease, renal cysts, glomerular disease and trauma can bleed. Proteinuria, dysmorphic red cells, casts, hypertension or impaired renal function may point toward nephrological disease, but renal and urothelial pathology can coexist. Anticoagulation may reveal bleeding from an underlying lesion rather than provide a complete explanation.
Other malignancies include renal-cell carcinoma, upper-tract urothelial carcinoma, prostate cancer invading the bladder and pelvic cancers involving urinary structures. In women, vaginal or cervical bleeding can be mistaken for haematuria; in all patients, careful history and examination should establish the likely source without delaying urinary assessment. Red urine can reflect beetroot, rifampicin, phenazopyridine, haemoglobinuria or myoglobinuria, but dipstick and microscopy help discriminate these from intact urinary red cells.
Cystoscopic mimics include cystitis, stones, radiation change, endometriosis, malakoplakia and benign lesions. Carcinoma in situ may appear as a flat erythematous patch or be occult under white light; positive high-grade cytology with a normal-looking bladder requires evaluation of bladder mucosa and extravesical urothelial sites rather than reassurance. Histological variants, squamous differentiation and adenocarcinoma require specialist pathology because management and likely primary site can differ. The safest reasoning principle is concordance: symptoms, cystoscopy, imaging, cytology and tissue must form a coherent explanation, and an apparently benign component cannot overrule persistent discordant evidence.
Management
Non-muscle-invasive bladder cancer begins with high-quality TURBT and risk stratification using stage, grade, size, number, recurrence pattern, concomitant carcinoma in situ and other pathological features. A second resection is required in defined incomplete, high-grade or T1 situations and when staging tissue is inadequate. Low-risk disease may be managed with complete resection and a protocol-appropriate immediate intravesical chemotherapy instillation when safe. Intermediate- and high-risk disease can require induction and maintenance intravesical therapy, commonly bacillus Calmette–Guérin for appropriate high-risk disease. Persistent or recurrent high-grade disease despite adequate BCG needs prompt expert discussion; repeated bladder-sparing attempts must not defer potentially curative cystectomy in a patient whose progression risk is unacceptable.
Muscle-invasive, non-metastatic disease is managed with curative intent when feasible. Options include radical cystectomy with pelvic lymph-node dissection, usually with perioperative systemic therapy in eligible patients, or carefully selected bladder-preserving trimodality treatment combining maximal TURBT, radiosensitising chemotherapy and radiotherapy with intensive response assessment. Choice depends on tumour features, hydronephrosis, bladder function, comorbidity, renal function, treatment access and informed preference. Diversion counselling must cover ileal conduit, continent options where suitable, stoma care, sexual and reproductive effects and lifelong metabolic or renal follow-up.
Locally advanced or metastatic urothelial cancer uses biomarker-, fitness- and availability-directed systemic treatment, local procedures and integrated supportive care. Obstruction may require drainage; haematuria, pain and bone or neurological complications need active palliation. Exact immunotherapy, antibody-drug conjugate, targeted-therapy and chemotherapy sequences change rapidly and must follow current Indian approval, product information and institutional protocol. Surveillance is risk-adapted: cystoscopy remains central after non-muscle-invasive disease, while post-definitive-treatment follow-up assesses recurrence, upper tracts, renal function, diversion complications and survivorship. Smoking cessation, rehabilitation, nutrition, continence and psychological support belong in the treatment plan.
Prescribing Information
Intravesical and systemic anti-cancer treatment is specialist prescribing. Before intravesical instillation, confirm the indication, agent, dose and dwell protocol; review urinalysis, current infection symptoms, traumatic catheterisation, visible haematuria, bladder integrity and recent resection. Immediate postoperative chemotherapy is withheld when perforation or significant bleeding is suspected. BCG is a live attenuated mycobacterial treatment, not conventional chemotherapy: it must not be given through a traumatic catheter or during significant symptomatic infection, and fever or systemic illness after instillation requires urgent assessment under the local BCG-toxicity pathway. Product handling, infection-control and waste procedures must follow institutional policy.
Before systemic therapy, verify histology, stage, measurable disease where applicable, treatment intent, performance status, renal and hepatic function, blood counts, hearing, neuropathy, heart failure, infection and autoimmune history, pregnancy potential and all medicines. Cisplatin eligibility is not determined by creatinine alone and requires protocol-specific assessment. Carboplatin is not automatically equivalent in curative perioperative settings. Checkpoint inhibitors can produce delayed immune-mediated toxicity affecting skin, bowel, liver, lung, endocrine organs, kidneys, heart or nervous system. Targeted agents require a validated biomarker and current regulatory indication. Antibody-drug conjugates and cytotoxics have product-specific risks, dose modifications and monitoring.
Give patients a functioning 24-hour contact route and written toxicity instructions. Fever, rigors, hypotension, breathlessness, uncontrolled diarrhoea, jaundice, confusion, severe rash, bleeding or reduced urine output warrants urgent review. Consider interactions, vaccination timing, fertility preservation and contraception before therapy. Analgesia, antiemetics, thromboprophylaxis, growth factors and antimicrobials are indication-specific rather than automatic. India-specific availability, biosimilar or generic policy, reimbursement and cold-chain capacity must be confirmed; a current guidelines or EAU recommendation does not establish Indian licensing or affordability. This guide intentionally provides no regimen, dose or cycle schedule because safe prescribing requires the current protocol, pharmacy verification and patient-specific laboratory thresholds.
When to Refer
Visible unexplained haematuria warrants prompt urological assessment, particularly when it is painless, recurrent or persists after treatment of documented infection. Non-visible haematuria accompanied by persistent urinary symptoms, abnormal renal findings or relevant risk factors also needs a structured pathway rather than serial empirical antibiotics. current guidelines' age thresholds are designed for a UK suspected-cancer service and can inform recognition, but they must not be copied as an Indian national referral rule. Younger age, female sex or anticoagulant use should not become reasons to ignore visible bleeding. Referral should include urinalysis and culture results, renal function, haemoglobin, medications, tobacco and occupational exposure, prior imaging and a clear account of whether blood was visibly urinary.
Emergency referral is required for clot retention, inability to void, haemodynamic compromise, severe ongoing bleeding, symptomatic anaemia, sepsis, acute kidney injury, bilateral obstruction or uncontrolled pain. Suspected spinal cord compression, pathological fracture, severe hypercalcaemic symptoms or acute neurological deterioration in known cancer also needs emergency care. Stable haematuria still requires timely evaluation even if it resolves before the appointment.
Once a tumour is found, refer to a urology cancer multidisciplinary team with specialist pathology and radiology. High-grade T1, carcinoma in situ, variant histology, muscle invasion, hydronephrosis or incomplete resection requires expedited coordination. Medical and radiation oncology input is necessary for perioperative therapy, bladder preservation or advanced disease; stoma nursing should precede planned diversion. Renal, geriatric, cardiology, infectious-disease, fertility, sexual-health, palliative-care and psychosocial services may be needed. In India, verify the receiving centre's capacity for TURBT quality, re-resection, intravesical supply, cystectomy, radiotherapy and toxicity management. A nominal referral without images, pathology material, navigation or a defined contact can create dangerous delay.
Red Flags
Macroscopic haematuria with clots, suprapubic pain and inability to pass urine suggests clot retention. Assess urgently because progressive bladder distension, ongoing blood loss and obstructive kidney injury can develop. Haemodynamic instability, syncope, chest pain, marked pallor or rapid haemoglobin fall requires resuscitation and urgent urological haemostasis planning. Fever, flank pain, hypotension or confusion may indicate infected obstruction or urosepsis; urinary drainage and antimicrobials should not wait for routine cancer staging. Anuria, rapidly worsening renal function or bilateral hydronephrosis is likewise time-critical.
Cancer-related red flags include new severe pelvic or bone pain, leg swelling suggesting venous or lymphatic obstruction, focal weakness, sensory change or bladder/bowel neurological dysfunction, and new breathlessness or haemoptysis. These may signal locally advanced disease, thrombosis or metastasis and require urgent assessment. Persistent haematuria after an apparently negative or incomplete evaluation is a process red flag: confirm that cystoscopy, upper-tract imaging and pathology were adequate and that cytology discordance was addressed.
Treatment emergencies differ by modality. After BCG, persistent high fever, rigors, hypotension, respiratory symptoms, jaundice or multisystem illness can represent disseminated BCG infection or severe inflammatory toxicity. During systemic treatment, fever or deterioration may be neutropenic sepsis; new diarrhoea, hepatitis, pneumonitis, endocrinopathy, myocarditis or neurological symptoms may be immune mediated. Following cystectomy or diversion, reduced stoma output, abdominal distension, vomiting, wound deterioration, fever, severe electrolyte symptoms or acute kidney injury needs urgent surgical review. Following chemoradiation, heavy bleeding, sepsis or inability to hydrate also requires escalation. Every treatment plan should state whom to contact after hours and where the patient should present.
Indian Clinical Context
India has no single uniform bladder-cancer pathway across public, teaching, charitable and private systems. A patient may undergo ultrasound, cystoscopy, TURBT, pathology review, staging and definitive treatment at different institutions. Preserve cystoscopy diagrams, operative notes, imaging in transferable format, histology blocks or slides and the complete pathology report. The presence of detrusor muscle in the specimen is a quality issue, not clerical detail; without it, an apparently non-muscle-invasive label may be unsafe. Access to expert genitourinary pathology, enhanced cystoscopy, re-resection, BCG, cystectomy, reconstructive options and radiotherapy varies substantially.
EAU and international guidelines guidance offers transparent evidence-based principles, but European risk groups, licensed medicines, surveillance schedules and service assumptions are not automatically Indian policy. Current Indian regulatory approval, institutional formulary, microbiological capacity and oncology protocol must govern treatment. BCG supply interruptions require documented multidisciplinary alternatives rather than silent dose or schedule improvisation. Where travel or cost threatens frequent cystoscopic surveillance, navigation should be escalated; reducing follow-up without documenting the added risk is not shared decision-making. Government benefit schemes and charitable support differ by state and institution, so eligibility should be checked, not promised.
The national IARC estimate is modelled and cannot substitute for local registry data. Occupational histories may be missed in informal-sector workers, and tobacco counselling must include regionally used smoked products. Schistosomiasis should be considered from actual endemic residence or freshwater exposure, including migration, not assumed from nationality. Women with haematuria are at risk of repeated infection treatment and delayed referral; confirm cultures and reassess resolution. Prehabilitation, anaemia correction, renal optimisation, stoma-site marking, caregiver training and reliable access to appliances materially affect outcomes after cystectomy. Language-concordant explanations should compare organ preservation with oncological safety honestly. Evidence gaps include Indian comparative-effectiveness and affordability data for rapidly evolving systemic sequences, making local tumour-board review indispensable.
NMC Competency Mapping
The NMC CBME 2024 curriculum supports undergraduate recognition and referral, not independent cancer treatment. Surgery competency SU29.10 specifically addresses bladder cancer within lower urinary tract teaching. Related surgery and medicine learning requires evaluation of haematuria and urinary symptoms, principles of investigation and recognition of urological emergencies. Pathology competencies on carcinogenesis, tumour grading, invasion and laboratory diagnosis support interpretation of urothelial specimens. Pharmacology contributes principles of anti-cancer drugs, adverse reactions, interactions and rational prescribing. Institutions should confirm the current wording and integration of these competencies before using them in a formal logbook.
A graduating student should take an exposure-aware haematuria history, distinguish visible from non-visible bleeding, assess stability, identify clot retention and infection, and explain why anticoagulation or apparent cystitis does not automatically end investigation. Under supervision, the learner should interpret urinalysis, blood count and renal function, recognise the role and limitations of ultrasound, CT urography, cytology and cystoscopy, and explain why TURBT provides both diagnosis and staging. They should distinguish Ta, T1, carcinoma in situ and muscle-invasive disease; understand grade, detrusor muscle sampling and the concept of multifocal urothelial field disease.
Management learning should remain principle-based: complete resection and risk-adapted intravesical therapy for non-muscle-invasive disease; cystectomy or selected trimodality treatment for muscle invasion; systemic and supportive care for advanced disease. Students should communicate uncertainty, obtain consent for intimate examination, avoid stigmatising tobacco or occupational exposure, and make an actionable referral. Reading cannot certify cystoscopy, TURBT, intravesical administration, stoma care or anti-cancer prescribing. Assessment should use clinical vignettes that test recognition of haematuria, staging boundaries, specimen quality and emergencies, while clearly separating educational knowledge from procedural privileges and tumour-board authority.
Key Exam Pearls for NEET PG
Painless intermittent visible haematuria is the classic presentation of bladder cancer, but dysuria, urgency and frequency can occur, especially with carcinoma in situ. Tobacco smoking is the leading modifiable risk factor; aromatic amine exposure is the classic occupational association. Schistosoma haematobium is linked particularly with squamous-cell carcinoma. Urothelial carcinoma is the commonest histology and may be multifocal throughout the urinary tract. A normal examination does not exclude early disease, and anticoagulant use does not remove the need to identify the bleeding source.
Cystoscopy is central to diagnosis and cannot be replaced by urine cytology or a urinary biomarker. Cytology is more useful for high-grade tumour and carcinoma in situ than for low-grade papillary lesions. TURBT is both diagnostic and therapeutic for visible non-muscle-invasive tumour. The specimen must allow assessment of grade and depth; detrusor muscle is crucial when invasion is in question. Ta is non-invasive papillary disease, T1 invades lamina propria, Tis is flat carcinoma in situ and T2 invades muscularis propria. Imaging stages upper tracts and invasive disease but does not replace tissue diagnosis.
Low-risk non-muscle-invasive disease differs fundamentally from high-grade T1 or carcinoma in situ. BCG is intravesical immunotherapy and severe systemic illness after instillation is an emergency. Muscle-invasive disease may receive neoadjuvant cisplatin-based systemic therapy followed by radical cystectomy, or selected bladder-preserving trimodality treatment. Cisplatin fitness depends on renal and other clinical factors. Urinary diversion can be incontinent or continent and carries renal, metabolic, bowel, sexual and stoma-related consequences. Recurrent high-grade disease after adequate BCG raises the question of early cystectomy. Clot retention, infected obstruction, neutropenic sepsis and neurological signs of spinal compression require emergency action rather than routine follow-up.
Frequently Asked Questions
Can blood in the urine be ignored if it occurs only once and then stops?
No. Bladder bleeding can be intermittent, so spontaneous clearing does not prove a benign cause. Visible unexplained haematuria needs timely clinical assessment. Infection, stones and medicines are considered, but a documented alternative must fit the course and persistent or recurrent bleeding requires urological evaluation.
Does a negative urine cytology test rule out bladder cancer?
No. Cytology is an adjunct with greater sensitivity for high-grade disease and carcinoma in situ than for low-grade tumours. A negative result cannot replace cystoscopy or appropriate upper-tract imaging when symptoms or risk justify investigation, and a positive result needs localisation within the urothelial tract.
Is every bladder cancer treated by removing the bladder?
No. Many non-muscle-invasive cancers are managed initially with transurethral resection and risk-adapted intravesical treatment and surveillance. Radical cystectomy is considered for muscle-invasive disease and selected very-high-risk or treatment-unresponsive non-muscle-invasive disease; some carefully selected patients may receive bladder-preserving trimodality treatment. The decision requires staging, pathology review, fitness assessment and informed multidisciplinary discussion.
Why is detrusor muscle in the TURBT pathology specimen important?
The key treatment boundary is invasion into muscularis propria. If the specimen lacks appropriate muscle, depth can be underestimated and risk classification may be unreliable. The multidisciplinary team may recommend repeat resection or further staging depending on tumour grade, completeness of resection and the full clinical picture.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic